Boehringer&Eli Lilly Have Marketing Authorization for Jentadueto Tablets

Boehringer Ingelheim and Eli Lilly and Company have received European Commission marketing authorization for Jentadueto (linagliptin/metformin hydrochloride) tablets.

Jentadueto is a new, single-tablet treatment option, taken twice daily, for adults with type 2 diabetes who need to improve control of their blood glucose.

The European Commission has approved Jentadueto for use alongside diet and exercise to improve glycemic control in adults with type 2 diabetes who are inadequately controlled on their maximally tolerated dose of metformin alone, metformin and a sulfonylurea, or those already being treated with the combination of linagliptin and metformin.

Boehringer medicine corporate senior vice president Klaus Dugi said the Boehringer Ingelheim and Eli Lilly and Company worldwide diabetes alliance will make JENTADUETO available to adult patients with type 2 diabetes across Europe.

"Many patients need more than one treatment to adequately manage their diabetes. JENTADUETO offers patients with type 2 diabetes a single-tablet dosing option to improve control of their blood sugar," Dugi added.

Jentadueto (linagliptin/metformin hydrochloride) tablets combine the DPP-4 inhibitor, linagliptin and metformin in a single tablet taken twice daily.